DexCom (DXCM) Scheduled to Post Earnings on Thursday

DexCom (NASDAQ:DXCM) will be announcing its earnings results after the market closes on Thursday, October 24th. Analysts expect the company to announce earnings of $0.44 per share for the quarter. DexCom has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 EPS. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

NASDAQ:DXCM opened at $69.90 on Thursday. DexCom has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a market cap of $27.80 billion, a P/E ratio of 45.10, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The stock’s 50-day simple moving average is $69.95 and its 200 day simple moving average is $101.15.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on DXCM shares. Wells Fargo & Company dropped their price objective on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Oppenheimer cut their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $145.00 to $75.00 in a research note on Friday, July 26th. UBS Group cut their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.73.

Insider Activity

In other DexCom news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.